Pharmena S.A. - Asset Resilience Ratio
Pharmena S.A. (PHR) has an Asset Resilience Ratio of 71.24% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2022)
This chart shows how Pharmena S.A.'s Asset Resilience Ratio has changed over time. Check PHR capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Pharmena S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Pharmena S.A..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł8.12 Million | 71.24% |
| Total Liquid Assets | zł8.12 Million | 71.24% |
Asset Resilience Insights
- Very High Liquidity: Pharmena S.A. maintains exceptional liquid asset reserves at 71.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pharmena S.A. Industry Peers by Asset Resilience Ratio
Compare Pharmena S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Galapagos NV
F:GXEA |
Biotechnology | 86.45% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Pharmena S.A. (2010–2022)
The table below shows the annual Asset Resilience Ratio data for Pharmena S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 3.02% | zł380.00K ≈ $104.58K |
zł12.58 Million ≈ $3.46 Million |
-1.76pp |
| 2019-12-31 | 4.78% | zł561.00K ≈ $154.40K |
zł11.74 Million ≈ $3.23 Million |
-22.81pp |
| 2012-12-31 | 27.59% | zł3.20 Million ≈ $879.86K |
zł11.59 Million ≈ $3.19 Million |
+13.43pp |
| 2011-12-31 | 14.16% | zł2.56 Million ≈ $703.20K |
zł18.05 Million ≈ $4.97 Million |
-5.53pp |
| 2010-12-31 | 19.68% | zł3.31 Million ≈ $911.03K |
zł16.82 Million ≈ $4.63 Million |
-- |
About Pharmena S.A.
Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including face, hair, and body care products, as well as dietary supplement. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. Pharmena S.A. was founded in 2002 and is based in Lódz… Read more